January 22, 2017 9:42 AM ET


Company Overview of Novo Nordisk, Inc.

Company Overview

Novo Nordisk, Inc. operates as a healthcare company that focuses on diabetes care. The company provides diabetes pharmaceuticals and insulin delivery systems. It also specializes in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company was incorporated in 1982 and is headquartered in Princeton, New Jersey. It has a manufacturing facility in Clayton, North Carolina; and a research and development center in Seattle, Washington. Novo Nordisk, Inc. operates as a subsidiary of Novo Nordisk A/S.

100 College Road West

Princeton, NJ 08540

United States

Founded in 1982





Key Executives for Novo Nordisk, Inc.

Age: 56
Senior Vice President of Finance and Operations
Age: 49
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
Age: 62
Corporate Vice President and General Counsel
Chief Compliance Officer and Vice President of Compliance
Compensation as of Fiscal Year 2016.

Novo Nordisk, Inc. Key Developments

Novo Nordisk Receives FDA Approval of Tresiba (Insulin Degludec Injection 100 U/Ml, 200 U/Ml) for Use in Children and Adolescents with Diabetes

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Tresiba (insulin degludec injection 100 U/mL, 200 U/mL), a once-daily, long-acting basal insulin, to be used in children and adolescents with diabetes. Tresiba, first approved by the FDA in September 2015, is now indicated to improve glycemic control in patients with type 1 and type 2 diabetes from the age of one through adulthood,1 making it the only basal insulin approved for both type 1 and type 2 diabetes in patients as young as 1 year old. Tresiba is a long-acting insulin that is released over time, has a 25 hour half-life and has a consistently flat and stable profile at steady state.1 Novo Nordisk submitted the supplemental New Drug Application (sNDA) based on the results of the BEGIN Young 1 trial, a multi-national, 26-week, phase 3b, randomized, controlled, open-label, parallel-group, treat-to-target non-inferiority trial with a 26-week extension. BEGIN Young 1 compared the efficacy and safety of Tresiba administered once-daily compared with Levemir (insulin detemir [rDNA origin] injection) administered once-daily or twice daily, both in combination with insulin aspart, a mealtime insulin, in children and adolescents with type 1 diabetes aged 1 to 17. The results showed that Tresiba in combination with insulin aspart effectively improved glycemic control. The most common adverse events were infection, hypoglycemia and hyperglycemia.3 The use of Tresiba in patients one year of age and older with type 2 diabetes mellitus is also supported by evidence from adequate and well-controlled studies in adults with type 2 diabetes.1 Once-daily Tresiba (insulin degludec injection 100 U/mL, 200 U/mL) is available in Novo Nordisk's latest insulin delivery device – FlexTouch – as a 100 units/mL or 200 units/mL pen. Tresiba U-100 FlexTouch can deliver up to 80 units of insulin in a single injection. Tresiba U-200 FlexTouch can dose up to 160 units in a single injection. FlexTouch is also the only prefilled insulin pen with no push-button extension.1 Eligible patients with commercial insurance can use the Tresiba Instant Savings Card to reduce co-pays to as low as $15 a month for up to 24 months. Eligibility and other restrictions apply.

Novo Nordisk, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-10-2017 10:00 AM

Novo Nordisk, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-10-2017 10:00 AM. Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States. Speakers: Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist.

Novo Nordisk, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-05-2016 04:50 PM

Novo Nordisk, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-05-2016 04:50 PM. Venue: The Ritz-Carlton, Laguna Niguel, California, United States. Speakers: Barbara Araneo, Innovation Sourcing Director.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novo Nordisk, Inc., please visit www.novonordisk-us.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.